Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

January 31, 2017

Conditions
Lymphoproliferative MalignanciesAcute Myeloid Leukemia
Interventions
DRUG

ZEN003365

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

63110

Washington University School of Medicine, St Louis

97477

Willamette Valley Cancer Institute and Research Center, Springfield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zenith Epigenetics

INDUSTRY

NCT02238522 - Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | Biotech Hunter | Biotech Hunter